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Abstract 
Obesity, as well as type 2 diabetes mellitus, is a significant issue for health policy because it is so widespread in 
the population as a whole, and because of the high risk of complications it carries. Serum lipase and pancreatic 
amylase concentrations are used in conjunction with clinical findings to diagnose pancreatic disorders. The aim 
of this study was to differentiate the alterations in fasting dyslipidemia and serum levels of pancreatic enzymes 
in lean diabetics and non-diabetic obese. Triglyceride, lipase and amylase were measured in the serum collected 
from overnight fasting 300 volunteers those were separated into 3 groups; control group (non-diabetic and with 
normal weight), diabetics (normal weight) group and obese (non-diabetic) group. In this study, serum levels of 
triglyceride, amylase and lipase were significantly changed in obese group when compared to control group. 
But, only of triglyceride and amylase were increased significantly in diabetic group when compared to control 
group. On the other hand, serum lipase showed significant increase diabetic group when compared to obese 
group. In conclusion, serum triglyceride and amylase concentrations were higher in obese subjects than those 
with normal weight. The results of this study illustrated that serum lipase concentrations were decreased in 
obese subjects but increased in diabetic patients compared to the normal healthy subjects. 
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1. Introduction  
Obesity was not seen until the 20thcentury that it became common. People become obese for several reasons, 
including eating of much more than they used to. This used to be the case just in developed nations - however, 
the trend has spread worldwide.  Also with the arrival of televisions, computers, video games, remote controls, 
washing machines, dish washers and other modern convenience devices, the majority of people are leading a 
much more sedentary lifestyle compared to their parents and grandparents [1]. In 1997 the World Health 
Organization (WHO) formally recognized obesity as a global epidemic. In June of 2013 the American Medical 
Association classified obesity as a disease with much controversy [2]. The rise in obesity has led to widespread 
calls for regular monitoring of changes in overweight and obesity prevalence in all populations. Comparable, 
up-to-date information about levels and trends is essential to quantify population health effects and to prompt 
decision makers to prioritize action [3]. Obesity is difficult to treat and has a high relapse rate. Most people who 
lose weight regain the weight within five years. Obesity was recently described as a risk factor of pancreatic 
cancer in combination with metabolic abnormalities [4]. 
Type 2 diabetes mellitus consists of an array of dysfunctions characterized by hyperglycemia and resulting from 
the combination of resistance to insulin action, inadequate insulin secretion, and excessive or inappropriate 
glucagon secretion. Poorly controlled type 2 diabetes is associated with an array of micro-vascular, macro-
vascular and neuropathic complications [5].  
Amylase (a-I. 4-glucan 4-glucanohydrolase, EC 3.2.1.1) is an enzyme that catalyzes the hydrolysis of starch into 
sugars. Amylase is present in the saliva of humans and some other mammals, where it begins the chemical 
process of digestion. The pancreas and salivary gland make amylase (alpha amylase) to hydrolyze dietary starch 
into disaccharides and polysaccharides which are converted by other enzymes to glucose to supply the body 
with energy [6].  
A lipase (glycerol ester hydrolase, EC 3.1.1.3) is an enzyme that catalyzes the hydrolysis of fats (lipids). Lipases 
perform essential roles in the digestion, transport and processing of dietary lipids. Human pancreatic lipase 
(HPL) is the main enzyme that breaks down dietary fats in the human digestive system, converts ingested 
triglyceride to mono-glycerides and two fatty acids. Some lipase activities are confined to specific 
compartments within cells while others work in extracellular spaces [7]. 
Amylase and lipase are enzymes produced by the pancreas that help to digest food. Determination of serum 
lipoprotein lipase activity has been advocated as a tool for diagnosing pancreatitis for several decades[6], but 
serum amylase activity determination continues to be more popular for this purpose because of confusion in the 
literature on the meaning of the term, “lipase,” and on the diagnostic usefulness of various types of “lipase” 
data[6, 7].The interpretation of a high amylase or lipase can be complex. The clinical history is critical. 
Asymptomatic patients should be thoroughly screened for conditions like chronic alcohol abuse, renal failure, 
pancreatic cancer, and other non-pancreatic conditions [8]. 
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2. Materials and Methods 
2.1. Study design: 
It was a cross-sectional study. 
2.2. Study area:  
This study was conducted in Khartoum state, Sudan. The samples for this study were collected from Dr. Isam 
diabetes center, Al-Ajyal hospital, Al-Afaf Specialized Clinics and Dr. Amel Hospital for Obstetrics and 
Gynaecology, and Alribat hospital. 
2.3. Study period 
The study was commenced in November, 2012 and ended in July, 2014. 
2.4. Sample size and study population 
The study included 100diabetic patients with normal weight (50 males and 50 females) with mean age of 
52.5± 8.3 years, and 100 obese (non-diabetic) volunteers (50 males and 50 females) with mean age of 49.5 ± 9.1 
years. The control group consisted of 100 healthy non-diabetic volunteers with normal weight (50 males and 50 
females) whose mean ages were matched (50.5 ± 9.8 years).  
2.5. Sampling 
Venous blood samples were withdrawn from all subjects after 10 hours overnight fasting. 10 ml venous blood 
was obtained from antecubital vein by standard venipuncture techniques without venous stasis[9], in SST gel 
separated serum tubes. Following collection, samples were left to clot and were centrifuged for 5 min at 15000 
RPM and analyzed immediately after separation. Some serum was separated and stored at -20°C for further use. 
2.6. Methods of estimation of serum amylase and serum lipoprotein lipase levels 
In this study, chemicals and reagents used for estimation were obtained from Mindray Company China, and the 
measurement was carried by chemistry auto analyzer (Mindray BS-200E Chemistry Analyzer).Serum amylase 
was measured using ELISA methods as described by [10]; while serum lipoprotein lipase was measured using a 
sandwich ELISA following the methods described by Yang and his colleagues [11]. 
2.7. Methods of body mass index (BMI) estimation [12]: 
The BMI calculates a value indicative of the fat content of the body by dividing the body weight by the square 
of body height. 
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2.8. Ethical clearance 
An ethical clearance of this study was approved by the ethical committee of Omdurman Islamic University. 
Informed consent was obtained from each participant before taking the samples. 
2.9. Statistical analyses of data 
The data obtained were expressed as mean values ± SD. Statistical analyses were performed using SPSS 
(Statistical Package for Social Sciences) version 11.5. Differences in mean values between groups were 
evaluated by a Student's t-test. P-value was statistically significant at P<0.05. 
Table 5: Criteria for classification of participants based on BMI 
Categories BMI 
Underweight Less than 18.5 
Normal weight 18.5 - 24.9 
Overweight 25 - 29.9 
Obese 30 or higher 
 
3. Results 
This study included three groups, those were obese, diabetic (DM) and the control groups, each group 
comprised of 100 volunteers.  All groups were in matched ages. Also, there were matches in duration between 
obese and diabetic groups. And also, there was a matching between control and diabetic groups, where both 
groups were in the normal weight (table 1). 
Table 1: Demographic and clinical features of subjects 
 
 
a insignificant variation between all groups; b insignificant variation between obese and diabetic groups; c  
insignificant variation between control and diabetic groups. 
 
Control Obese  DM 
Number 100 100 100 
Gender 
Males 50 50 50 
Females 50 50 50 
Age 50.5 ± 9.8 49.5 ± 9.1 52.5± 8.3a 
Duration (years) 0 6 ± 3.9 6.5 ± 4b 
BMI (kg/m 2) 22.3 ± 4.1 34.7 ± 6.8 24.7 ± 9.6c 
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As in table 2, the serum levels of triglyceride, amylase and lipase were significantly changed in obese group 
when compared to control group. 
Table 3 showed that serum levels of triglyceride and amylase were significantly increased in diabetic group 
when compared to control group. 
In table 4, serum lipase in diabetic group showed significant increase when compared to obese group. 
 
Table 2: comparison of triglyceride, amylase and lipase levels between obese and control groups 
Groups Triglycerides(mg/dl)   Amylase (U/L) Lipase (U/L) 
Control  92.5 ± 10.1 42.1 ± 12.7 83 ± 12.7 
Obese  173 ± 11.1 110 ± 18.1 56.1 ± 18.5 
P value 0.000 0.000 0.046 
 
Table 3: comparison of triglyceride, amylase and lipase levels between diabetic and control groups 
Groups Triglycerides(mg/dl)   Amylase (U/L) Lipase (U/L) 
Control  92.5 ± 10.1 42.1 ± 12.7 83 ± 12.7 
Diabetes 169 ± 10.3 89.6 ± 9.5 95.3 ± 54 
P value 0.010 0.000 0.088 
 
Table 4: comparison of triglyceride, amylase and lipase levels between obese and diabetic groups 
Groups Triglycerides(mg/dl)   Amylase (U/L) Lipase (U/L) 
Obese  173 ± 11.1 110 ± 18.1 56.1 ± 18.5 
Diabetes 169 ± 10.3 89.6 ± 9.5 95.3 ± 54 
P value 0.104 0.091 0.002 
4. Discussion 
Most of the metabolic abnormalities associated with obesity have been shown to normalize with weight loss and 
thus are likely a consequence of the obese state, not a cause [1]. While diabetes mellitus is known to have a 
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deleterious metabolic abnormalities, that eventually contribute to diabetes-associated vascular complications [5].  
There is a close association between obesity and type 2 diabetes. The likelihood and severity of type 2 diabetes 
are closely linked with body mass index (BMI) [3].  
In the present study, the results of serum triglyceride and serum amylase were increased significantly in obese 
group when compared to control group (p value = 0.000); while serum lipase level was decreased significantly 
in obese group comparing to control (p value<0.05). In a previous study, Malloy and his colleagues [13] 
reported that results of amylase and lipase increased in the serum of obese persons may be due obesity and 
elevated triglyceride in the blood. 
The results of the present study also showed that the serum lipase levels were insignificantly increased in 
diabetic group than those in control group (p value>0.05). On the other hand, in diabetic group, the serum 
results of triglyceride and amylase were increased significantly (p value<0.05). These results were consistent 
with report of Tirosh and his colleagues [14] showing that elevated triglyceride levels are a common 
dyslipidemic feature accompanying type 2 diabetes and pre-diabetic states. Also, Yang and his colleagues [11] 
reported that the type 2 diabetic population is likely to have pancreatic enzyme elevations. 
Our results suggest that relatively higher LPL may be associated with type 2 diabetes in lean patients in the 
background of elevated triglyceride and serum amylase. The explanation of this could be related to low leptin 
level in lean patients, which related to distribution of body fat. For a given BMI, central rather than lower body 
fat distribution, confers greater risk of metabolic and cardiovascular complications of obesity [15]. Intra-
abdominal fat tissues secrete less leptin than subcutaneous fat tissue [16]. In addition, Sayeed and his colleagues 
[17] stated that leptin is reduced in lean subjects with type 2 diabetes in Bangladesh. Furthermore, Obesity is 
typically associated with high leptin levels and not leptin deficiency [18]. Studies investigated effect of leptin on 
diabetes concluded that long-term leptin replacement therapy improves glycemic control [19-21]. 
Serum triglyceride and amylase levels showed insignificant increase in obese group more than diabetic patient 
in this study (p value>0.05); while serum lipase level was decreased significantly in obese group when 
compared to diabetics (p value<0.05). Gajda and his colleagues [22] published that triglyceride was increased 
significantly in obese subjects more than in diabetic patients. Such results were contrary to what found in this 
study about triglycerides. Also, the results of the present study showed that amylase concentration was 
insignificantly increased in obese subjects more than in diabetic subjects (p value>0.05). In contrast, the lipase 
enzyme concentration was found to be increased significantly in diabetic group more than obese group (p 
value<0.05). Bojadzievski and his colleagues [23] reported that although the direct mechanism by which 
diabetes increases the susceptibility to higher pancreatic enzyme concentrations is unknown, insulin resistance 
and hyperglycemia appear to be important factors linked to the increase in pancreatitis in individuals with type 2 
diabetes. 
So, this research is recommended to maintain the ideal weight due to problems facing obese persons; on the 
other hand, the diabetic patients should keep the blood glucose within the normal rate and care to reduce weight 
as much as possible. 
100 
 
International Journal of Sciences: Basic and Applied Research (IJSBAR)(2015) Volume 23, No  2, pp 95-103 
5. Conclusion 
Overall, obese subjects had higher serum triglyceride and amylase concentrations than those with normal 
weight.  The results of this study displayed that serum lipase concentrations were decreased in obese subjects 
but increased in diabetic patients comparing to the control. 
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